The study to identify risk of botulinum toxin treatment failure due to the antibody

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220525004

Enrollment

500

Registered

2022-05-25

Start date

2021-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy human volunteers, Patient with history of botulinum toxin treatment failure. Enzyme-Linked Immunosorbent Assay, Botulinum Toxins, Immunoglobulins, Antibodies

Interventions

Blood is drawn from the subject with history of botulinum toxin treatment failure. The history of botulinum toxin usage from the subject is taken. The blood is analysed via ELISA method to detect botu

Experimental Other

Subject with toxin treatment failure

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Male or Female with history of botulinum toxin treatment failure No history of chronic disease

Exclusion criteria

Exclusion criteria: Subject who using immunosuppressive medication

Design outcomes

Primary

Measure	Time frame
Antibody level At the beginning of the study ng/ml	—

Secondary

Measure	Time frame
History of botulinum toxin usage At the beginning of the study Patient reported outcome using a questionnaire interview	—

Countries

Thailand

Contacts

Public ContactSurachet Sirisuthivoranunt

Faculty of Medicine Siriraj Hospital, Mahidol University

siri.surachet@gmail.com024199933

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026